An open-label study to analyze the effect on response and disease progression of capecitabine (Xeloda) in metastatic colorectal cancer patients with regard to the expression profile of key enzymes in the capecitabine metabolism.

Trial Profile

An open-label study to analyze the effect on response and disease progression of capecitabine (Xeloda) in metastatic colorectal cancer patients with regard to the expression profile of key enzymes in the capecitabine metabolism.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 May 2010

At a glance

  • Drugs Capecitabine; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Status changed from active, no longer recruiting to completed as reported by Roche record.
    • 02 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top